Diptoindonesin G

Diptoindonesin G is a 2-arylbenzofuran derivative and a modulator of estrogen receptor and HSP90 middle domain. Diptoindonesin G exhibits strong cytotoxicity against mouse leukemia P-388 cells with an IC50 of 13.2 μM. Diptoindonesin G has antitumor activity and can be used in the research of tumors such as breast cancer[1][2][3].

Product Specifications

CAS Number

[1190948-58-3]

UNSPSC

12352005

Target

Estrogen Receptor/ERR; HSP

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C1C2=C3C(OC(C4=CC=C(O)C=C4)=C3C5=C1C(O)=CC(O)=C5)=CC(O)=C2

Molecular Formula

C21H12O6

Molecular Weight

360.32

References & Citations

[1]Juliawaty LD, et al. A 2-arylbenzofuran derivative from Hopea mengarawan. Nat Prod Commun. 2009 Jul;4 (7) :947-50.|[2]Liu JT, et al. Total synthesis of diptoindonesin G and its analogues as selective modulators of estrogen receptors. Org Biomol Chem. 2016 Sep 26;14 (38) :8927-8930.|[3]Donahue K, et al. Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment. J Biol Chem. 2022 Dec;298 (12) :102700.